Benjamin H. Lowentritt, MD, FACS, Discusses Future Analyses for the Phase 3 SPOTLIGHT Trial in Recurrent Prostate Cancer

Video

Future focuses following the phase 3 SPOTLIGHT trial will include identifying sites of recurrence and different intensity levels for 18F-rhPSMA-7.3 in suspected recurrent prostate cancer, according to Benjamin H. Lowenritt, MD, FACS.

In an interview with CancerNetwork® during the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Benjamin H. Lowentritt, MD, FACS, a practicing urologist at Chesapeake Urology in Baltimore, Maryland, highlighted next steps for the phase 3 SPOTLIGHT study (NCT04186845), which examined the impact of clinical factors on detection rates of 18F-rhPSMA-7.3 in suspected recurrent prostate cancer. In terms of future analyses, Lowentritt indicated that assessing sites of disease recurrence and levels of intensity will be areas of focus.

Transcript:

The SPOTLIGHT trial data are really just coming to light and being reported. We're continuing to look at different subgroup analyses. [We are] also really drilling into some of the sites of recurrence and identifying where and when this may be most helpful. [We are] evaluating different levels of intensity, the [standardized uptake value], and other things within the actual imaging reports and how that may predict sites of disease. There is certainly continuing to be a lot of work done with the data from the SPOTLIGHT trial, which was only recently completed.

Reference

Lowentritt, B. Impact of clinical factors on 18F-rhPSMA-7.3 detection rates in men with recurrent prostate cancer: findings from the phase 3 SPOTLIGHT study. Presented at 2022 American Society for Radiation Oncology Annual Meeting (ASTRO); October 23-26, 2022; San Antonio, TX. Abstract 1049. Accessed November 3, 2022.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
Related Content